Orlistat
Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet
Empros Pharma AB · Phase 2 · Completed · Enrollment 486
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebos. | Obesity or overweight | n/r | n/r | n/r | n/r |
| Velneperit 400 mg | Obesity or overweight | 400 mg | n/r | n/r | n/r |
| Orlistat 120 mg | Obesity or overweight | 120 mg | n/r | n/r | n/r |
| Velneperit 400 mg + Orlistat 120 mg | Obesity or overweight | 120 mg | n/r | n/r | n/r |